Press release
United Therapeutics Corporation Reports First Quarter 2023 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022.\n\n\n“The hard work and determination of our over 1,000 Unitherians during the first quarter of this year allowed us to reach over $500 million in revenue for the second quarter ever,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer. “And to sustain our mission to help patients in need, our clinical team continues to progress our four registration studies in progress: the two TETON studies of Tyvaso in idiopathic pulmonary fibrosis, the ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension, and the clinical study of our CLES ex vivo lung perfusion technology.”\n\n\n“We are extremely pleased with the underlying strength of our Tyvaso franchise, highlighted by record referrals and starts during the quarter and net patient additions in line with prior quarters,” said Michael Benkowitz, President and Chief Operating Officer. “Our other core products also performed well, led by Orenitram which achieved record revenues in the first quarter.”\n\n\n\n\nFirst Quarter 2023 Financial Results\n\n\n\n\n\n\n\n\nKey financial highlights include (dollars in millions, except per share data):\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\n\nThree Months Ended\n\n\n\n\nMarch 31,\n\n\n\n\n\n\n \n\n\n\n\n\n\nDollar\nChange\n\n\n\n\n\n\n \n\n\n\n\n\n\nPercentage\nChange\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n2023\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n2022\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nTotal revenues\n\n\n\n\n\n\n$\n\n\n\n\n\n\n506.9\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n461.9\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n45.0\n\n\n\n\n\n\n \n\n\n\n\n\n\n10\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nNet income\n\n\n\n\n\n\n$\n\n\n\n\n\n\n240.9\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n239.9\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n1.0\n\n\n\n\n\n\n \n\n\n\n\n\n\n—\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nNet incom...